Skip to main content

Advertisement

SpringerLink
Log in

Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients

  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Abstract

The objective of this study was to provide support for a body weight-tiered dosing regimen by characterizing abatacept pharmacokinetics (PK) and the relationship between exposure and the ACR20 (American College of Rheumatology criteria for 20% improvement) response in Japanese patients with rheumatoid arthritis (RA). A population PK model was developed using NONMEM with 2,535 samples from 344 Japanese RA patients in two clinical trials. The exposure–response relationship was characterized using a Generalized Estimating Equation (GEE) logistic regression model, with time-varying actual trough concentrations and ACR20 responder rates over 6 months in a randomized, placebo-controlled phase 2 trial for stable methotrexate. Abatacept exposure was well characterized using a linear, two-compartment model, in which body weight and the empirically calculated glomerular filtration rate were significant covariates for clearance. The ACR20 response model was developed by examining the quasi-likelihood information criterion, and the cumulative logit in the final model was specified by the log-transformed trough concentration. The predicted ACR20 responder rate was consistent with the actual values in the clinical trial and this model revealed trough concentrations higher than the recommended body weight-tiered dose are unlikely to result in substantial increases in clinical efficacy. Considering that ACR20 is a longitudinal binary variable and the response to RA treatment is delayed, the GEE model was useful for predicting the probability of an ACR20 response. In conclusion, the same dosing regimen as non-Japanese patients is recommended because a body weight-tiered dosing regimen achieves similar exposures across the wide range of body weight.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Genovese MC, Becker J-C, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114–1123

    Article  PubMed  CAS  Google Scholar 

  2. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG, Ochs HD, Kelley SL, Kang S (1999) CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103:1243–1252

    Article  PubMed  CAS  Google Scholar 

  3. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker J-C, Hagerty DT, Moreland LW (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349:1907–1915

    Article  PubMed  CAS  Google Scholar 

  4. Goldring SR (2002) Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 14:406–410

    Article  PubMed  Google Scholar 

  5. Hoffman RW (2001) T cells in the pathogenesis of systemic lupus erythematosus. Front Biosci 6:D1369–D1378

    Article  PubMed  CAS  Google Scholar 

  6. Goronzy JJ, Weyand CM (2004) T-cell regulation in rheumatoid arthritis. Curr Opin Rheumatol 16:212–217

    Article  PubMed  CAS  Google Scholar 

  7. Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233–258

    Article  PubMed  CAS  Google Scholar 

  8. Silver PB, Hathcock KS, Chan CC, Wiggert B, Caspi RR (2000) Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol 165:5041–5047

    PubMed  CAS  Google Scholar 

  9. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916

    Article  PubMed  CAS  Google Scholar 

  10. Maxwell LJ, Singh JA (2010) Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 37:234–245

    Article  PubMed  CAS  Google Scholar 

  11. Ma Y, Lin B-R, Lin B, Hou S, Qian W-Z, Li J, Tan M, Ma J, Li B-H, Wang H, Wen A-D, Guo Y-J (2009) Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. Acta Pharmacol Sin 30:364–371

    Article  PubMed  CAS  Google Scholar 

  12. Davis PM, Nadler SG, Rouleau KA, Suchard SJ (2005) Abatacept (CTLA4-Ig) modulates human T-cell proliferation and cytokine production but does not affect lipopolysaccharide-induced tumor necrosis factor alpha production by monocytes. Arthritis Res Ther 7(suppl 1):21

    Article  Google Scholar 

  13. Roy A, Mould DR, Wang XF, Tay L, Raymond R, Pfister M (2007) Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. J Clin Pharmacol 47:1408–1420

    Article  PubMed  CAS  Google Scholar 

  14. ICON (2007) NONMEM7™ user’s guide. http://www.globomaxnm.com/nonmem.htm. Accessed Mar 2011

  15. Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA (1984) Regression modeling strategies for improved prognostic prediction. Stat Med 3:143–152

    Article  PubMed  Google Scholar 

  16. Bradburn MJ, Clark TG, Love SB, Altman DG (2003) Survival analysis part III: multivariate data analysis—choosing a model and assessing its adequacy and fit. Br J Cancer 89:605–611

    Article  PubMed  CAS  Google Scholar 

  17. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F (2007) Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53:766–772

    Article  PubMed  CAS  Google Scholar 

  18. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Hirakata H, Watanabe T, Moriyama T, Ando Y, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S (2007) Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11:41–50

    Article  PubMed  Google Scholar 

  19. Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV (2003) Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol 43:610–623

    PubMed  CAS  Google Scholar 

  20. Liang KY, Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13–22

    Article  Google Scholar 

  21. Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC (2003) Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73:348–365

    Article  PubMed  CAS  Google Scholar 

  22. Pan W (2001) Akaike’s information criterion in generalized estimating equations. Biometrics 57:120–125

    Article  PubMed  CAS  Google Scholar 

  23. Yasuoka Y, Goto A, Seriu T (2011) Pharmacological properties and clinical efficacy of abatacept (Orencia®) for the treatment of rheumatoid arthritis. Nippon Yakurigaku Zasshi 137:87–94 Japanese

    Article  PubMed  CAS  Google Scholar 

  24. Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G (2008) Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 30:523–529

    PubMed  CAS  Google Scholar 

  25. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK (2003) Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25:1700–1721

    Article  PubMed  CAS  Google Scholar 

  26. Bristol-Myers K.K. (2010) Orencia (abatacept) [prescribing information]. http://www.orencia.jp. Accessed Mar 2011

  27. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS (2001) Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 41:1206–1214

    Article  PubMed  CAS  Google Scholar 

  28. Tang L, Persky AM, Hochhaus G, Meibohm B (2004) Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93:2184–2204

    Article  PubMed  CAS  Google Scholar 

  29. Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645–2668

    Article  PubMed  CAS  Google Scholar 

  30. Sun YN, Lu JF, Joshi A, Compton P, Kwon P, Bruno RA (2005) Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol 45:468–476

    Article  PubMed  CAS  Google Scholar 

  31. Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171–192

    Article  PubMed  CAS  Google Scholar 

  32. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, Paulus H, Tugwell P, Weinblatt M, Widmark R, Williams HJ, Wolfe F (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 36:729–740

    Article  PubMed  CAS  Google Scholar 

  33. Hempel G, Karlsson MO, de Alwis DP, Toublanc N, McNay J, Schaefer HG (1998) Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements. Clin Pharmacol Ther 64:622–635

    Article  PubMed  CAS  Google Scholar 

  34. Trocóniz IF, de Alwis DP, Tillmann C, Callies S, Mitchell M, Schaefer HG (2000) Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine. Clin Pharmacol Ther 68:18–27

    Article  PubMed  Google Scholar 

  35. Mandema JW, Stanski DR (1996) Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 60:619–635

    Article  PubMed  CAS  Google Scholar 

  36. Holford NH, Peace KE (1992) Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA 89:11466–11470

    Article  PubMed  CAS  Google Scholar 

  37. Gomeni R, Teneggi V, Iavarone L, Squassante L, Bye A (2001) Population pharmacokinetic-pharmacodynamic model of craving in an enforced smoking cessation population: indirect response and probabilistic modeling. Pharm Res 18:537–543

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We have no conflict of interest regarding our article.

Author information

Authors and Affiliations

  1. Pharmacometrics, Research and Development, Bristol-Myers K.K., Shinjuku i-Land Tower, 6-5-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 163-1328, Japan

    Mayumi Hasegawa, Yasuhiko Imai & Masaki Hiraoka

  2. Research Institute of Pharmaceutical Sciences, Musashino University, 1-1-20 Shinmachi, Nishitokyo, Tokyo, 202-8585, Japan

    Mayumi Hasegawa & Kiyomi Ito

  3. Research and Development, Bristol-Myers Squibb, Princeton, NJ, 08543-4000, USA

    Amit Roy

Authors
  1. Mayumi Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasuhiko Imai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masaki Hiraoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kiyomi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amit Roy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mayumi Hasegawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hasegawa, M., Imai, Y., Hiraoka, M. et al. Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn 38, 803–832 (2011). https://doi.org/10.1007/s10928-011-9221-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-011-9221-5

Keywords

Search

Navigation